王亚莉，魏蜀亮，赖应龙，贾维心血管支架置入与凝血反应。
Wang Y. -L. , Wei S. -L. , Lai Y. -L. , Jia W. -K. Implantation of cardiovascular stent and coagulation response.
谢潮鑫，孟猛，曾伟杰，钟磊，魏春霞，罗佼心血管支架材料生物力学及生物相容性与支架置入后血管再狭窄。
Xie C. -X. , Meng M. , Zeng W. -J. , Zhong L. , Wei C. -X. , Luo J. Biomechanics and biocompatibility of cardiovascular stent materials and restenosis following stent implantation.
由此可建议，PLA 肝素聚合体对于与血液相接触的材料是有用的，特别是可以用于心血管组织的支架材料中。
These results suggest that PLA-heparin polymer would be useful in blood contacting materials, especially in scaffold materials in cardiovascular tissue engineering.
目的：探讨在不锈钢冠状动脉支架上携带质粒基因，为心血管再狭窄基因治疗的临床应用提供试验依据。
Objective: to investigate stainless steel coronary stent-based plasmid gene delivery system and evaluate its feasibility and effectiveness to gene therapy of cardiovascular restenosis.
目的：从材料学及临床应用方面阐述如何提高老年心血管疾病中药物涂层支架的相容性。
OBJECTIVE: To investigate how to elevate the compatibility of drug-eluting stent in elderly cardiovascular disease from aspects of material and clinical application.
另外，有24%药物支架病人出现了重大的心血管事件，相比之下，放疗组该比例仅为9.8%。
In addition, 24% of DES patients experienced major cardiovascular events compared to 9.8% of radiation patients.
为此心血管医生会在球囊上套一段金属筛网状支架并放置在梗塞部位以保持血管的畅通。
To solve the problem, cardiologists put pieces of wire mesh called stents around the balloons. The stents remain in place as a piece of scaffolding to try to keep the arteries open.
术后6个月重复冠状动脉造影，比较两组间的晚期管腔丢失、支架再狭窄率及术后心血管不良事件发生率。
Coronary angiography was performed at the 6th month. The late lumen loss, stent restenosis and major adverse cardiac events were compared in both groups.
药物治疗是减少冠心病介入术后支架内再狭窄、降低远期主要心血管事件的主要手段。
Medicine treatment plays key role in reducing the rate of restenosis and major adverse cardiac events.
药物治疗是减少冠心病介入术后支架内再狭窄、降低远期主要心血管事件的主要手段。
Medicine treatment plays key role in reducing the rate of restenosis and major adverse cardiac events.
应用推荐